Citius Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Dec 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 27, 2024
CTXR$0.53-3.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| 2024 | 2023 | |
|---|---|---|
| Revenues | $— | $— |
| Operating Expenses: | ||
| Research and development | 11,906,601 | 14,819,729 |
| General and administrative | 18,249,402 | 15,295,584 |
| Stock-based compensation – general and administrative | 11,839,678 | 6,616,705 |
| Total Operating Expenses | 41,995,681 | 36,732,018 |
| Operating Loss | (41,995,681) | (36,732,018) |
| Other Income: | ||
| Interest income, net | 758,000 | 1,179,417 |
| Gain on sale of New Jersey net operating losses | 2,387,842 | 3,585,689 |
| Total Other Income Net | 3,145,842 | 4,765,106 |
| Loss before Income Taxes | (38,849,839) | (31,966,912) |
| Income tax expense | 576,000 | 576,000 |
| Net Loss | (39,425,839) | (32,542,912) |
| Net loss attributable to non-controlling interest | 287,000 | - |
| Deemed dividend on warrant extension | (1,047,312) | (1,151,208) |
| Net Loss Applicable to Common Stockholders | $(40,186,151) | (33,694,120) |
| Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted | $(5.97) | (5.57) |
| Weighted Average Common Shares Outstanding | ||
| Basic and diluted | 6,726,999 | 6,051,789 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.